People: Agenus Inc (AGEN.O)

AGEN.O on Consolidated Issue listed on NASDAQ Capital Market

23 Apr 2014
Price Change (% chg)

$-0.06 (-2.21%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Wentworth, Kerry 

Brief Biography

Ms. Kerry A. Wentworth serves as Vice President - Clinical, Regulatory & Quality of Agenus Inc., since June 2006. Before joining Agenus Inc. in 2005, Ms. Wentworth served as senior director of regulatory affairs at Genelabs Technologies, where she was responsible for the business’ regulatory and quality functions. There she focused on the late-stage clinical development and subsequent US and European commercial application filings for the company’s lead product Prestara. Prior to Genelabs, Ms. Wentworth held various positions in regulatory affairs at Shaman Pharmaceuticals and at Genzyme Corporation. Ms. Wentworth received a BS in pre-veterinary medicine from the University of New Hampshire.

Basic Compensation

Total Annual Compensation, USD Long-Term Incentive Plans, USD All Other, USD Fiscal Year Total, USD
301,540 -- 333,629 824,366

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

G Armen


Christine Klaskin


Robert Stein


Karen Valentine


Kerry Wentworth


Timothy Wright

As Of 30 Dec 2012
Search Stocks